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which result is more convincing. Altered miRNA expression has
been clearly linked to liver cancer, but the molecular mecha-
nisms by which miRNA modulates hepatocarcinogenesis are still
unknown. The reasons for their controversial study results are
complex; we think lack of consideration of risk factors for
chronic HBV-related HCC in these studies may be one of the
key reasons.
In summary, well designed and systematic studies are still
needed to clarify the molecular mechanism that leads to deregu-
lation of miRNA expression in HBV-associated multistep hepato-
carcinogenesis. Incorporating HBV DNA level, sex, age, cigarette
smoking, alcohol consumption, chemical carcinogens, hormonal
factors, and genetic susceptibility when investigating the rela-
tionship between deregulation of miRNA expression and HCC
may be helpful in resolving the controversies.
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a statistically signiﬁcant deregulation of miR-21, miR-221, miR-
10b, and miR-122 in early stages of hepatocarcinogenesis, our
ﬁndings in no way excluded the possibility of deregulation of
these miRNAs in later stages of HCC. In fact, we found that
miR-221 and miR-122 were signiﬁcantly deregulated in early
stages of HCCs when compared to the non-tumorous liver sam-
ples (p <0.001, post test with Bonferroni correction, Supplemen-
tary Fig. 1). An increasing trend was also observed with miR-21
when small HCCs were compared with the non-tumorous livers.
These ﬁndings were actually in line with those of the previous
reports [2–4].
In principle, we agree with Yin et al. that risk factors may
affect the miRNA expression pattern in HCCs. In our study, we
focused on the miRNA deregulation in HBV-associated HCC [1].
Indeed, the HCC samples used in the above-mentioned studies
had substantially different etiological backgrounds when com-
pared to our sample cohort. Kutay et al. mainly focused on pre-
malignant nodules and HCC samples obtained from foliate and
methyl-deﬁcient (FMD) diet-fed Fisher 334 rats, while the risk
factors of the three human HCC samples in their study were
not described [3]. In the study of Pineau et al. the HCC samples
Letters to the EditorTo the Editor:
Yin et al. drew attention to the differences between the ﬁndings
on miR-221, miR-21 and miR-122 deregulation in hepatocarcino-
genesis reported in our recent study [1] and others [2–4]. Yin
et al. further speculated that the inconsistence of the ﬁndings
among these reports might be due to different risk factors for
HCC and called for further investigations on this subject.
In our article, we reported ﬁndings on the expression levels of
seven cancer-related miRNAs in a series of chronic hepatitis/cir-
rhotic livers, dysplastic nodules (DNs) and small HCC samples.
We found that miR-145, miR-199b and miR-224 were signiﬁ-
cantly deregulated in early stages of hepatocarcinogenesis (DN
and small HCCs) when compared to the corresponding non-
tumorous livers. The evidence for miR-21, miR-221, miR-10b
and miR-122 deregulation was less clear and the data did not
reach the stringent statistical threshold employed for that study
(p <0.001 for one-way ANOVA and post tests with Bonferroni cor-
rection for multiple comparisons). However, we have to empha-
size that our analysis mainly focused on the early stages of
hepatocarcinogenesis and whether a miRNA was deregulated in
DNs and small HCCs. Although our ﬁndings failed to demonstrate1426 Journal of Hepatology 2012 vol. 56 j 1420–1429
were mainly (>75%) HCV-associated [4], and the risk factor was
different from that of our samples. For the 19 HCC samples used
by Connolly et al., nine were HBsAg positive but the HBV status
was not available in the remaining 10 cases. In addition, these
HCC samples were collected from Qidong area of Jiangsu Province
of China, where aﬂatoxin B1 is a common risk factor of HCC [2].
The diversity of the etiological background of the samples,
together with the various experimental approaches involved,
very much hinders direct comparison of data among the different
studies. For this reason, experimentally uniﬁed and well con-
trolled studies on large sample cohorts are required to investigate
the effects of different etiological factors on miRNA deregulation
in human HCCs.
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Is a liver biopsy necessary in alcoholic hepatitis?
To the Editor:
The paper by Mookerjee et al. allowed a fascinating insight into
the prognostic relevance of the systemic inﬂammatory response
(SIRS) in decompensated alcoholic liver disease (ALD), especially
the presence of alcoholic steatohepatitis (ASH) [1]. However, the
paper makes some assertions which require further discussion.
The main assertion is that a liver biopsy is essential to deter-
mine the diagnosis and prognosis in patients with ASH. Not only
is this contrary to recently published guidelines [2], there are
practical issues in obtaining and interpreting transjugular liver
biopsies. Few liver centres in the United Kingdom can readily
provide such a service. In 2009/10 there were 14,700 hospital
admissions in England alone for alcoholic liver disease: 5700 with
‘‘alcoholic cirrhosis’’ and 1600 with ‘‘alcoholic hepatitis’’ [3].
Mookerjee et al. describe biopsies in 71 patients over a 3-year
period. The provision of transjugular liver biopsies throughout
the rest of the United Kingdom and Europe for the thousands of
additional ALD patients is unrealistic. A management strategy
based upon an impractical level of investigation will not beneﬁt
most patients with ALD. We must ensure that we can assess
and effectively manage these patients in all hospitals and not
solely in limited specialist centres.
With regards to the need for biopsy for diagnosis of alcoholic
hepatitis, the ﬁgure of 70–80% accuracy of a clinical diagnosis
subsequently conﬁrmed by biopsy is often quoted [2]. However,
the most consistent difference between patients with alcoholic
hepatitis and other patients with decompensated ALD is the
degree of hyperbilirubinaemia [4,5]. A recent review of all the
randomised controlled trials of treatments for alcoholic hepatitis
determined the accuracy of the clinical criteria used relative to
subsequent histological conﬁrmation. If only those studies, which
used a minimum level of bilirubin (ranging from 80 to 100 lmol/
L) or whose patient population had a lower limit of bilirubin
greater than 80 lmol/L, were considered, the accuracy of a clini-
cal diagnosis rose to 96% [6]. This is very similar to a group of
patients with ALD presenting with Acute-on-Chronic Liver Failure
(ACLF) which has recent onset of hyperbilirubinaemia (>85 lmol/
L) as a major tenant of its deﬁnition [7]. In this group of patients
again, 96% had features of ASH. In the paper by Mookerjee, the
criteria for a clinical diagnosis of ASH appear to have been
decompensated ALD with the presence of SIRS without a mini-
mum value of bilirubin stipulated. ‘‘Progressive jaundice’’ was
just one of three criteria used to deﬁne the patient group studied.
Furthermore, no information was provided regarding duration of
liver disease at time of biopsy. Previous experience indicates that
the accuracy of clinical diagnosis of alcoholic hepatitis is highest
if the biopsy is performed within 4 weeks of initial presentation
[8].
Whilst Maddrey’s Discriminant Function (DF) has been a land-
mark advance in the assessment of alcoholic hepatitis, its accu-
racy is in question not least of all because it relies upon the
measured prolongation of the prothrombin time, which is prone
to signiﬁcant laboratory variation. Additionally, in the paper by
Mookerjee, the DF was not found to be predictive of 28-day out-
come. More recently, the MELD score and the Glasgow Alcoholic
Hepatitis Score (GAHS) have been shown to identify poor out-
come from alcoholic hepatitis [2,9]. These have similar AUC val-
ues to those described for the histological ASH grade described
in the paper by Mookerjee et al. The paper did not demonstrate
that their histological data were independently predictive of sur-
vival or added signiﬁcantly to the predictive value of these scores.
The development of a reproducible histological score for alcoholic
hepatitis is to be applauded. However, even in this specialist cen-
tre there was a delay of up to 7 days before the biopsies were
obtained. With the additional time for preparation and interpre-
tation of the specimens, the delay in obtaining a prognosis from
histological criteria is signiﬁcant and the opportunity to inter-
vene early in those patients who may beneﬁt may be lost. How-
ever, clinical scores such as the GAHS, readily calculable on the
day of admission and over subsequent days, are not only accurate
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